Can spinal cord stimulation effectively reduce muscle spasms in an adult patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Spinal Cord Stimulation for Muscle Spasms

Yes, spinal cord stimulation (SCS) is an effective treatment for reducing muscle spasms in patients with spinal cord injury, with both epidural and transcutaneous approaches demonstrating significant clinical benefit.

Evidence for Efficacy

The evidence strongly supports SCS for spasm control in spinal cord injury patients. A prospective study of 48 patients with spinal cord injury showed statistically significant reduction in spasm severity that progressively increased over time at 3,6,12, and 24-month follow-ups, with no neurological deterioration 1. This represents the highest quality prospective evidence available for this indication.

Mechanism and Technical Requirements

For optimal spasm control, four critical factors must be met 2:

  • Electrode placement: Must be positioned over the upper lumbar cord segments (L1-L3)
  • Stimulation parameters: Frequency of 50-100 Hz, amplitude 2-7V, pulse width 210 microseconds
  • Contact optimization: Systematically test different combinations of the quadripolar electrode contacts
  • Position-dependent adjustment: Amplitudes must be adjusted for different body positions

The mechanism works by enhancing pre- and post-synaptic spinal inhibitory mechanisms rather than suppressing excitatory inputs 3. This is crucial because recent research demonstrates that spasms after SCI stem from impaired synaptic inhibition and increased motoneuron excitability, not from increased excitatory inputs 4. This makes SCS mechanistically superior to pharmacological approaches that suppress excitation and can hinder motor recovery.

Transcutaneous vs. Epidural Approaches

Transcutaneous SCS (Non-invasive)

Transcutaneous SCS offers a non-invasive alternative with meaningful carry-over effects. A 2020 study showed that single 30-minute sessions at 50 Hz (sub-threshold intensity) produced significant reductions in stretch-induced spasticity, clonus, and spasms immediately after treatment, with effects persisting 2 hours post-intervention 3.

Electrode placement for transcutaneous approach: Two electrodes paravertebrally at T11-T12 level and two on lower abdomen 5.

In a multi-session study, weekly evaluations suggested progressively improving therapeutic effects over 6 weeks with carry-over effects lasting 7 days 3. Seventeen patients reported clinically important improvements (≥2 points on NRS) in ADL performance, sleep disturbance, and/or pain reduction, with no adverse events 5.

Epidural SCS (Invasive)

Epidural approaches provide more robust and sustained effects but require surgical implantation. The 1995 prospective study demonstrated progressive improvement over 24 months 1, and a 2000 study confirmed that when correctly positioned and programmed, epidural SCS is "highly effective" for controlling severe spasticity 2.

Clinical Decision Algorithm

Start with transcutaneous SCS if:

  • Spasms are moderate and interfering with function, sleep, or causing pain
  • Patient can self-administer treatment at home
  • Trial period needed to assess responsiveness before considering invasive options

Progress to epidural SCS if:

  • Spasms are severe and refractory to medical therapy
  • Patient has demonstrated response to transcutaneous trial
  • At least 6 months post-injury (chronic phase)
  • Long-term sustained control is needed

Comparative Context

A 2025 review notes that surgical methods (except intrathecal baclofen) can lower muscle tone long-term, while botulinum toxin and intrathecal baclofen provide only short-term relief with controversial functional improvement 6. SCS occupies a unique position as it can reduce spasms while potentially preserving or enhancing motor recovery, unlike pharmacological approaches that suppress excitatory pathways needed for motor function.

Safety Profile

No neurological deterioration has been reported with either approach 1, 5, 3. The transcutaneous method is particularly safe as it's completely non-invasive and reversible.

Common Pitfalls to Avoid

  • Incorrect electrode positioning: Placement outside L1-L3 segments will fail to control spasms
  • Inadequate parameter optimization: Must systematically test different contact combinations and adjust for body position
  • Wrong frequency selection: Must use 50-100 Hz range; other frequencies are ineffective
  • Premature intervention: Wait at least 6 months post-injury for chronic phase stabilization

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.